Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/
Location: Netherlands, Utrecht
Employees: 51-200
Total raised: $157.12M
Founded date: 2003
Investors 5
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Aglaia Onc... | aglaia-onc... |
| - | Bay City C... | baycitycap... |
| - | Life Scien... | lspvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 26.08.2015 | Series C | $82.49M | - |
| 20.05.2015 | Grant | $2.33M | - |
| 03.10.2013 | Series B | $42.17M | - |
| 29.01.2010 | Series B | $30.13M | - |
Mentions in press and media 22
| Date | Title | Description |
| 12.08.2024 | Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates | USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to impro... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 05.03.2024 | Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression | - |
| 03.11.2022 | Merus Announces Financial Results for the Third Quarter and Provides Business Update | – Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics – Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potenti... |
| 26.10.2022 | Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics | - MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels - Initial recommended phase 2 dose 1500 mg every two ... |
| 02.12.2021 | Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021 | UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodi... |
| 02.11.2021 | Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update | Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus presented early clinical data on MCL... |
| 30.09.2021 | Merus N : Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibod... |
| 20.12.2019 | Bill Lundberg takes over the reins at Merus; Former Akcea COO Jeffrey Goldberg takes the helm of Immunitas | Bill Lundberg → Dutch biotech Merus, who struck up a $200 million bispecific development deal with Incyte in 2016, is losing their CEO Ton Logtenberg. Meanwhile, the company has nominated Sven (Bill) Ante Lundberg to be Lo... |
| 27.01.2017 | Jounce Therapeutics prices IPO beyond expectations (Updated) | The early stage biotech company, with a focus on cancer immunotherapy and targeted therapeutics, has raised $102 million in private funding to date, from investors such as Third Rock. Jounce is listed on the NASDAQ Capital Market under the ... |
Show more